Shanghai Xidi Pharmaceutical

Xidi Pharma is a clinical-stage biotechnology company headquartered in Shanghai, China, focused on developing breakthrough therapies for central nervous system (CNS) disorders. The company's core strength lies in its proprietary X-Delivery platform, which utilizes endogenous transport systems to facilitate the delivery of therapeutic agents across the blood-brain barrier. Their lead program, XD-002, is a brain-penetrant small molecule currently in Phase 1 clinical trials for the treatment of glioblastoma multiforme. Beyond neuro-oncology, Xidi Pharma is advancing a pipeline of candidates targeting brain metastases and various neurodegenerative conditions. By overcoming the challenge of drug delivery to the brain, the company aims to transform the treatment landscape for patients with severe neurological diseases.